Study Estimates Worldwide Prevalence of 25 Adult Cancers

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 2
Volume 11
Issue 2

LYON, France-A study from the International Agency for Research on Cancer (IARC) shows a higher cancer prevalence in the developed world, primarily because of longer life expectancy in richer countries (Int J Cancer 97:72-81, 2002).

LYON, France—A study from the International Agency for Research on Cancer (IARC) shows a higher cancer prevalence in the developed world, primarily because of longer life expectancy in richer countries (Int J Cancer 97:72-81, 2002).

The study examined the prevalence of 25 adult cancers for 11 world areas using data from IARC for developing countries, US SEER, and EUROCARE I. The study described the number of cancer cases diagnosed between 1986 and 1990 among individuals aged 15 or older who were still alive at the end of 1990.

Lead author Paola Pisani, reported the highest cancer prevalence in North America at 1.5%. Western Europe and Australia/New Zealand had a prevalence of 1.2% and 1.1%, respectively, followed by Japan at 1%, Eastern Europe at 0.7%, and Latin American and the Caribbean at 0.4%. The lowest prevalence (0.2%) was found in sub-Saharan Africa, the Middle East and Northern Africa, and Southeastern and South Central Asia.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Related Content